Settlements for generic and biosimilar drugs have led to significant healthcare cost savings, although delays in market entry still persist for some products. Despite agreements accelerating potential entry for drugs like Welchol, Integrilin, Aggrastat, and Istodax, regulatory and supply chain challenges have hindered their availability. While patent disputes are resolved through settlements, other factors can impede timely access to affordable medications. This highlights the importance of addressing regulatory and supply issues to fully realize the benefits of early generic and biosimilar settlements.
Read more from centerforbiosimilars.com
